My ePortfolio Register   

WIN Symposium 2017 /
Current and future immune approaches in precision medicine

26th - 27th Jun 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.07.17
Views: 472

Prof Jean -Yves Blay - Centre Léon Bérard, Lyon, France

Prof Blay speaks with ecancer at WIN 2017 about open questions and the future of research in immunotherapy.

Among the avenues to explore, Prof Blay outlines the variation in patients response rates and duration, with hyper-progressors posing as much a mystery as best responders.

He lists multiple subtypes across diseases, offering a vast ocean of disease stratification that may never be fully charted, but notes that innovations in trial design and treatment combinations offer chances of achieving the most benefit for even rare diseases.

Prof Blay notes changing availability and cost of genome sequencing and liquid biopsy as opening new futures in bioinformatics, with physics and mathematics coming to the fore in biological understandings of disease and data.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence